Ernexa Therapeutics Inc. (ERNA) Return on Sales (2010 - 2024)
Ernexa Therapeutics' (ERNA) quarterly Return on Sales came in at 20.42% in Q4 2024, up 2168.0% YoY from 0.9% in Q1 2024, and up 3837.89% on a QoQ basis from 0.55% in Q3 2024.
Ernexa Therapeutics Inc. (ERNA) Return on Sales (2010 - 2024) Analysis & Trends
Ernexa Therapeutics (ERNA) has 14 years of Return on Sales data on file, last reported at 20.42% in Q4 2024.
- Quarterly Return on Sales rose 2168.0% year-over-year to 20.42% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.0% (up 217.0% YoY) and the FY2024 annual result came in at 0.0%, up 217.0% from the prior year.
- Return on Sales improved to 20.42% in Q4 2024, from 0.55% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 20.42% in Q4 2024 to a low of 1.41% in Q1 2024.
- A 4-year average of 1.24% and a median of 0.03% in 2020 frame the typical range for Return on Sales.
- The widest YoY moves for Return on Sales: up 2168 bps in 2024, down 145 bps in 2024.
- Tracing ERNA's Return on Sales over 4 years: stood at 0.04% in 2020, then sank by 101 bps to 0.0% in 2022, then slumped by 512231 bps to 1.26% in 2023, then surged by 1726 bps to 20.42% in 2024.
- The last three Return on Sales figures came in at 20.42% (Q4 2024), 0.55% (Q3 2024), and 1.18% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 20.42% |
| Sep 30, 2024 | -0.55% |
| Jun 30, 2024 | -1.18% |
| Mar 31, 2024 | -1.41% |
| Dec 31, 2023 | -1.26% |
| Sep 30, 2023 | -1.10% |
| Mar 31, 2023 | 0.03% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | -0.06% |
| Dec 31, 2020 | 0.04% |
| Sep 30, 2020 | -0.01% |
| Mar 31, 2020 | -0.01% |
| Dec 31, 2019 | 0.00% |
| Sep 30, 2019 | 0.00% |
| Jun 30, 2019 | 0.00% |
| Mar 31, 2019 | 0.00% |
| Dec 31, 2018 | 0.00% |
| Sep 30, 2018 | 0.00% |
| Jun 30, 2018 | 0.00% |
| Mar 31, 2018 | 0.00% |